Effects of Rosiglitazone on Insulin Resistance,Resting and Exercise Blood Pressure in Type 2 Diabetes Mellitus Patients with Coronary Artery Heart Disease
OBJECTIVE:To evaluate the effects of rosiglitazone on insulin resistance,resting and exercise blood pressure in patients with type 2 diabetes mellitus(T2DM)complicated with coronary artery heart disease(CHD).METHODS:Totally 258 patients with T2DM complicated with CHD admitted into the First Affiliated Hospital of Xi'an Jiaotong University from Nov.2021 to Oct.2022 were extracted to be randomly divided into the rosiglitazone group and control group via the random number table method,with 129 cases in each group.All patients were given routine treatments such as antiplatelet aggregation,blood sugar control,and blood lipid regulation.The rosiglitazone group was additionally treated with oral Rosiglitazone tablets at a dose of 4 mg/time,once a day.All patients were treated continuously for 12 months.The anthropometric indicators,biochemical indicators,resting and exercise blood pressure,and the incidence rate of exercise-induced hypertension were compared between the rosiglitazone group and control group before and after treatment.RESULTS:After treatment,the body weight(t=3.339,P＜0.001),body mass index(t=3.093,P=0.002)and subcutaneous adipose tissue(t=5.086,P＜0.001)of the rosiglitazone group increased significantly compared with the control group;after treatment,the adiponectin(t=15.135,P＜0.001)in the rosiglitazone group increased significantly compared with the control group,while the glycosylated hemoglobin(t=4.305,P＜0.001),fasting blood glucose(t=5.190,P＜0.001),and homeostatic model assessment of insulin resistance indicator(t=6.815,P＜0.001)decreased significantly compared with the control group;after treatment,the systolic and diastolic blood pressure of the rosiglitazone group decreased significantly compared with the control group at rest,3 minutes during exercise,peak exercise,1 minute after exercise,3 minutes after exercise,and 5 minutes after exercise(P＜0.05),with statistically significant differences.After treatment,the incidence of exercise-induced hypertension in the rosiglitazone group was significantly lower than that in the control group,with statistically significant differences[11.6％(15/129)vs.29.5％(38/129),x2=12.562,P＜0.001].CONCLUSIONS:Rosiglitazone can significantly improve insulin resistance,resting and exercise blood pressure in T2DM patients with CHD,reduce the incidence of exercise-induced hypertension,and improve the exercise ability of patients.
Type 2 diabetes mellitusCoronary artery heart diseaseRosiglitazoneBlood pressure
万方数据
维普
